{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["capmatinib"]],"indication":null,"name":"GEOMETRY-N","nct_id":"NCT04926831","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=geometry-n-nct04926831. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"Geometry-N","arms":[{"description":"The study treatment started on Cycle 1 Day 1 with the first administration of capmatinib 400 mg twice a day (b.i.d.). The participants were planned to receive study treatment for a maximum of 3 years following surgery or until early discontinuation.","label":"Cohort A (MET exon 14 skipping mutations)","type":"EXPERIMENTAL"},{"description":"The study treatment started on Cycle 1 Day 1 with the first administration of capmatinib 400 mg twice a day (b.i.d.). The participants were planned to receive study treatment for a maximum of 3 years following surgery or until early discontinuation.","label":"Cohort B (high MET amplification)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-03-13","type":"ACTUAL"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":4,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"capmatinib","otherNames":["INC280"],"type":"DRUG"}],"last_update":"2025-10-16","lead_sponsor":"Novartis Pharmaceuticals","official_title":"Phase II Trial of Neoadjuvant and Adjuvant Capmatinib in Participants With Stages IB-IIIA, N2 and Selected IIIB (T3N2 or T4N2) NSCLC With MET Exon 14 Skipping Mutation or High MET Amplification (Geometry-N)","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2024-03-13","type":"ACTUAL"},"primary_outcomes":[{"measure":"Major Pathological Response (MPR) Rate","timeFrame":"Baseline up to time of surgery (approximately 8 to 10 weeks after first dose)"}],"references":[],"start_date":{"date":"2022-08-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC","url":"https://clinicaltrials.gov/study/NCT04926831"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/geometry-n-nct04926831"}